These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 23296171)

  • 1. Coming full circle in diabetes mellitus: from complications to initiation.
    Harcourt BE; Penfold SA; Forbes JM
    Nat Rev Endocrinol; 2013 Feb; 9(2):113-23. PubMed ID: 23296171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches to prevention of cardiovascular complications and events in diabetes mellitus.
    Coccheri S
    Drugs; 2007; 67(7):997-1026. PubMed ID: 17488145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Caveolin-1 in Diabetes and Its Complications.
    Haddad D; Al Madhoun A; Nizam R; Al-Mulla F
    Oxid Med Cell Longev; 2020; 2020():9761539. PubMed ID: 32082483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-glucans in the treatment of diabetes and associated cardiovascular risks.
    Chen J; Raymond K
    Vasc Health Risk Manag; 2008; 4(6):1265-72. PubMed ID: 19337540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute and chronic animal models for the evaluation of anti-diabetic agents.
    Kumar S; Singh R; Vasudeva N; Sharma S
    Cardiovasc Diabetol; 2012 Jan; 11():9. PubMed ID: 22257465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced changes in risk/biomarkers and their relationship with renal and cardiovascular long-term outcome in patients with diabetes.
    Miao Y; Smink PA; de Zeeuw D; Lambers Heerspink HJ
    Clin Chem; 2011 Feb; 57(2):186-95. PubMed ID: 21159899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes - mechanisms and potentials for treatment.
    Giaccari A; Sorice G; Muscogiuri G
    Nutr Metab Cardiovasc Dis; 2009 Jun; 19(5):365-77. PubMed ID: 19428228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of Insulin Resistance, Endothelial Dysfunction and Lifestyle Changes in the Development of Cardiovascular Disease in Diabetic Patients.
    Sun D; Man W; Zhang L
    Curr Drug Targets; 2017; 18(15):1792-1799. PubMed ID: 27425648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular disease in diabetes.
    Yamagishi S; Nakamura K; Matsui T; Takenaka K; Jinnouchi Y; Imaizumi T
    Mini Rev Med Chem; 2006 Mar; 6(3):313-8. PubMed ID: 16515470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.
    Spallarossa P; Barsotti A; Cordera R; Ghigliotti G; Maggi D; Brunelli C
    J Endocrinol Invest; 2004 May; 27(5):485-95. PubMed ID: 15279085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correction of pathological conditions associated with insulin-resistant hyperglycaemia].
    Solovyeva EY; Karneev AN; Tyutyumova EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9):116-125. PubMed ID: 28635729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tissue renin-angiotensin-aldosterone system in diabetes mellitus.
    Hanes DS; Nahar A; Weir MR
    Curr Hypertens Rep; 2004 Apr; 6(2):98-105. PubMed ID: 15010011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial and detrimental effects of intensive glycaemic control, with emphasis on type 2 diabetes mellitus.
    Camacho P; Pitale S; Abraira C
    Drugs Aging; 2000 Dec; 17(6):463-76. PubMed ID: 11200307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.
    Yamagishi S; Maeda S; Matsui T; Ueda S; Fukami K; Okuda S
    Biochim Biophys Acta; 2012 May; 1820(5):663-71. PubMed ID: 21440603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More insights on the dysglycaemia-cardiovascular connection.
    Gerstein HC
    Lancet; 2010 Jun; 375(9733):2195-6. PubMed ID: 20609955
    [No Abstract]   [Full Text] [Related]  

  • 16. Strategies for the development of new PPAR agonists in diabetes.
    Cavender MA; Nicholls SJ; Lincoff AM
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S32-7. PubMed ID: 20489419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of antioxidants in redox regulation of diabetic cardiovascular complications.
    Turan B
    Curr Pharm Biotechnol; 2010 Dec; 11(8):819-36. PubMed ID: 20874678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatment guidelines for a patient with diabetes and hypertension.
    Mogensen CE
    J Hypertens Suppl; 2003 Mar; 21(1):S25-30. PubMed ID: 12769164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of cardiovascular events in diabetes mellitus: implications for hypertension management.
    Lim HS; MacFadyen RJ; Bakris G; Lip GY
    Curr Pharm Des; 2006; 12(13):1567-79. PubMed ID: 16729870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus.
    McGuire DK; Winterfield JR; Rytlewski JA; Ferrannini E
    Diab Vasc Dis Res; 2008 Mar; 5(1):59-66. PubMed ID: 18398815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.